Literature DB >> 26523493

Irreversible Electroporation in Patients with Hepatocellular Carcinoma: Immediate versus Delayed Findings at MR Imaging.

Siddharth A Padia1, Guy E Johnson1, Raymond S Yeung1, James O Park1, Daniel S Hippe1, Matthew J Kogut1.   

Abstract

PURPOSE: To assess the postprocedure findings of irreversible electroporation (IRE) in patients with hepatocellular carcinoma (HCC) at magnetic resonance (MR) imaging.
MATERIALS AND METHODS: This retrospective study was Institutional Review Board approved, and informed consent was waived. Twenty patients with HCC were treated with IRE over a 2.5-year period. The median patient age was 62 years, and 75% of patients had cirrhosis with a Child-Pugh score of A. The median tumor diameter was 2.0 cm (range, 1.0-3.3 cm). Contrast material-enhanced multiphase MR imaging was performed on postprocedure days 1 and 30 and every 90 days thereafter. Ablation zone sizes and signal intensities were compared between each time point for both T1- and T2-weighted images. Trends in signal intensity and tumor dimensions over time were quantified by using generalized linear models.
RESULTS: MR imaging appearances of treated tumors include a zone of peripheral enhancement with centripetal filling on delayed contrast-enhanced images. Compared with postprocedure day 1, every 90 days there is a decrease of 28.9% (mean, axis) in the size of the enhancing ablation zone. Over time, there is a trend toward decreasing signal intensity in the peripheral ablation zone on both T2-weighted (P = .01) and contrast-enhanced T1-weighted (P < .08) images. Conversely, the tumor itself typically has increased signal intensity on the same sequences.
CONCLUSION: IRE of HCC results in a large region of enhancement on immediate postprocedure MR images that, over time, involutes and is associated with decreasing signal intensity of the peripheral ablation zone. This phenomenon may represent resolution of the reversible penumbra. © RSNA, 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26523493     DOI: 10.1148/radiol.2015150031

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

1.  Preclinical and clinical evaluation of the liver tumor irreversible electroporation by magnetic resonance imaging.

Authors:  Matteo Figini; Xifu Wang; Tianchu Lyu; Zhanliang Su; Daniele Procissi; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  DWI and DCE-MRI approaches for differentiating reversibly electroporated penumbra from irreversibly electroporated ablation zones in a rabbit liver model.

Authors:  Anna J Shangguan; Chong Sun; Bin Wang; Liang Pan; Quanhong Ma; Su Hu; Jia Yang; Aydin Eresen; Yuri Velichko; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

3.  Predicting irreversible electroporation-induced tissue damage by means of magnetic resonance electrical impedance tomography.

Authors:  Matej Kranjc; Simona Kranjc; Franci Bajd; Gregor Serša; Igor Serša; Damijan Miklavčič
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

Review 4.  Irreversible electroporation in primary and metastatic hepatic malignancies: A review.

Authors:  Tianchu Lyu; Xifu Wang; Zhanliang Su; Junjie Shangguan; Chong Sun; Matteo Figini; Jian Wang; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

Review 5.  Ablation of hepatic malignant tumors with irreversible electroporation: A systematic review and meta-analysis of outcomes.

Authors:  Guo Tian; Qiyu Zhao; Fen Chen; Tian'an Jiang; Weilin Wang
Journal:  Oncotarget       Date:  2017-01-24

Review 6.  Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives.

Authors:  Asha Zimmerman; David Grand; Kevin P Charpentier
Journal:  J Hepatocell Carcinoma       Date:  2017-03-13

7.  Irreversible Electroporation for the Ablation of Renal Cell Carcinoma: A Prospective, Human, In Vivo Study Protocol (IDEAL Phase 2b).

Authors:  Mara Buijs; Krijn P van Lienden; Peter Gk Wagstaff; Matthijs Jv Scheltema; Daniel M de Bruin; Patricia J Zondervan; Otto M van Delden; Ton G van Leeuwen; Jean Jmch de la Rosette; M Pilar Laguna
Journal:  JMIR Res Protoc       Date:  2017-02-16

8.  Intraprocedural Transcatheter Intraarterial Perfusion (TRIP)-MRI for Evaluation of Irreversible Electroporation Therapy Response in a Rabbit Liver Tumor Model.

Authors:  Anna J Shangguan; Kang Zhou; Jia Yang; Aydin Eresen; Bin Wang; Chong Sun; Liang Pan; Su Hu; Ali T Khan; Samdeep K Mouli; Vahid Yaghmai; Zhuoli Zhang
Journal:  Clin Exp Gastroenterol       Date:  2020-11-06

Review 9.  A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Authors:  Vincenza Granata; Roberta Fusco; Simona Salati; Antonella Petrillo; Elio Di Bernardo; Roberta Grassi; Raffaele Palaia; Ginevra Danti; Michelearcangelo La Porta; Matteo Cadossi; Gorana Gašljević; Gregor Sersa; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

10.  Magnetic Resonance Imaging Findings After Percutaneous Irreversible Electroporation of Liver Metastases: A Systematic Longitudinal Study.

Authors:  Alexandra Barabasch; Martina Distelmaier; Philipp Heil; Nils Andreas Krämer; Christiane K Kuhl; Philipp Bruners
Journal:  Invest Radiol       Date:  2017-01       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.